Earning Analysis
Welcome to our in-depth analysis of Addex Therapeutics Ltd(ADXN) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Addex Therapeutics Ltd earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| - | 2025-12-04 | Pre-Market | - | -1.50 | - | - | 62.50K | - | -6.78 | - |
| - | 2025-06-19 | Pre-Market | - | -1.33 | - | - | 78.93K | - | +1.05 | +5.36 |
| FY2024Q4 | 2025-04-25 | Pre-Market | - | -1.37 | - | 150.00K | 1.72K | -98.85 | +11.78 | +6.74 |
| FY2024Q3 | 2024-11-22 | Pre-Market | -1.40 | -2.77 | -97.86 | 110.00K | 58.35K | -46.95 | -7.15 | +7.40 |
| FY2024Q2 | 2024-09-30 | Pre-Market | -0.07 | 10.61 | +15257.14 | 221.00K | 115.28K | -47.84 | +7.96 | +4.31 |
| - | 2024-06-06 | - | - | -1.37 | - | - | - | - | +2.34 | -5.45 |
| FY2023Q4 | 2024-04-18 | - | - | -4.06 | - | 651.00K | 153.45K | -76.43 | -4.73 | -29.32 |
| FY2023Q3 | 2023-11-29 | - | 4.00 | -4.07 | -1.75 | 641.00K | 329.00K | -48.67 | +0.26 | +1.93 |
| - | 2022-08-18 | - | -0.56 | -1.18 | -110.71 | - | - | - | +3.10 | -5.43 |
| - | 2022-05-05 | - | -0.52 | -0.97 | -86.54 | - | - | - | +7.93 | -13.74 |
ADXN Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Addex Therapeutics Ltd reported performance for , announced on 2025-12-04. The company achieved an EPS of -1.50, compared to analyst estimates of by % . Revenue for the quarter reached 62.50K compared to expectations of 0.00 by % .
The stock price reacted with a -6.78% one-day change and a % five-day change following the earnings release. These movements reflect market reaction in Addex Therapeutics Ltd growth trajectory and strategic initiatives.
ADXN Earnings Forecast
Looking ahead, Addex Therapeutics Ltd(ADXN) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 200.00K and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q3 2025, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a 7.86% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Addex Therapeutics Ltd long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between ADXN's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q3 2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+7.86%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:750.00K
--
EPS Estimate-Annual FY 2025:-0.05
—
Stock Price8.38
ADXN Revenue and EPS Performance: A Historical Perspective
Addex Therapeutics Ltd revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
(2025-12-04,Pre-Market):
EPS: -1.50 (Actual) vs. (Estimate) (%)
Revenue: 62.50K (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -6.78%(1-Day), %(5-Day)
(2025-06-19,Pre-Market):
EPS: -1.33 (Actual) vs. (Estimate) (%)
Revenue: 78.93K (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 1.05%(1-Day), 5.36%(5-Day)
FY2024Q4 (2025-04-25,Pre-Market):
EPS: -1.37 (Actual) vs. (Estimate) (%)
Revenue: 1.72K (Actual) vs. 150.00K (Estimate) (-98.85%)
Price Reaction: 11.78%(1-Day), 6.74%(5-Day)
Earnings Reaction
The chart below shows how ADXN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ADXN sees a +1.04% change in stock price 10 days leading up to the earnings, and a -9.56% change 10 days following the report. On the earnings day itself, the stock moves by +1.01%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed % on the day following the earnings release and then changed by 0% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Summary
Neutral
2025-12-04
The earnings call reflects a mixed outlook. The financial performance remains stable, but with increased liabilities and reliance on partnerships, there's uncertainty. The Q&A reveals concerns about competitive pressures and funding needs. Positive aspects include potential milestone payments and strategic repositioning of programs. However, the lack of specific guidance and increased liabilities weigh down sentiment, leading to a neutral stock price prediction.
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Summary
Negative
2025-10-01
Despite some positive elements like debt reduction and service levels, the overall sentiment is negative due to declining sales, margins, and EPS. Inflation, weak consumer sentiment, and higher tariff costs are significant concerns. The Q&A section did not provide clarity, adding uncertainty. The expectation of declining sales in Q2 and lower operating margins further contribute to the negative outlook. The impact of divestitures and foreign exchange headwinds exacerbates the situation, leading to a likely negative stock price movement in the short term.
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Summary
Negative
2025-10-01
The earnings call highlights financial and operational challenges, including a limited cash runway, dependency on partnerships, and increased liabilities. The need for additional financing and the company's reliance on external collaborations pose significant risks. Despite some positive developments in the neuropsychiatry space, the Q&A session revealed management's evasiveness on strategic details, further contributing to uncertainty. Overall, these factors suggest a negative sentiment and potential stock price decline.
Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Summary
Negative
2025-04-25
The earnings call summary reveals several concerns: decreased income, reliance on partnerships, and lack of a clear shareholder return plan. While there are some positive aspects, such as decreased expenses and a small financial gain, the overall sentiment is negative due to the significant decrease in income and the risk factors highlighted in the Q&A section. The lack of strong positive catalysts or new partnerships, combined with the low market cap and dilution risk, suggests a negative stock price movement over the next two weeks.
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Summary
Positive
2024-11-22
The earnings call summary highlights strong financial performance with a 25% increase in revenue and reduced net loss. The partnership with Indivior and a share repurchase program further boost sentiment. Despite some risks and lack of specific guidance, the overall outlook is optimistic with new product launches and improved cash position. The Q&A session did not reveal significant negative sentiment from analysts, supporting a positive stock price reaction.
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Summary
Neutral
2024-09-30
The earnings call summary presents a mixed picture. While the financial health and cash position have improved, revenue has significantly decreased. The Neurosterix transaction is promising, yet regulatory and financial risks loom. The Q&A section indicates some uncertainties, especially regarding the clinical path for the chronic cough program. Overall, the positive aspects are balanced by significant risks and uncertainties, leading to a neutral sentiment rating.
People Also Watch
FAQ
What were the key highlights of ADXN’s latest earnings report for ?
How did ADXN’s stock price react after the earnings release?
What are the revenue and EPS estimates for ADXN for 2025/Q3?
How does ADXN’s stock price correlate with earnings forecast revisions?
What should investors expect from ADXN’s next earnings report?